Effect of the nonsteroidal anti-inflammatory drug 480156-S on hepatic drug-metabolizing activity and pharmacological action of diazepam and pentobarbital in rats.

Takashi Matsubara, Katsumi Hirose, Hisao Hatakeyama, Hirokuni Jyoyama, Akira Touchi, Shigemi OtsuboFolia 1988 · DOI

Introduction

Drug-drug interactions (DDIs) represent a significant clinical concern, particularly when one medication alters the metabolic clearance of another. This study, published in the Japanese Journal of Pharmacology, examines the interaction potential of 480156-S, a propionic acid derivative nonsteroidal anti-inflammatory drug (NSAID).

Chemical structure of the novel NSAID 480156-S.

Previous clinical observations suggested that 480156-S might inhibit oxidative metabolism in the liver. The researchers aimed to characterize this inhibition, determine its specificity across Cytochrome P-450 (P-450) isozymes, and evaluate its impact on the pharmacological duration of co-administered drugs like diazepam and pentobarbital.

Methods

The study utilized male and female Wistar and SD rats. Hepatic drug-metabolizing activity was assessed by measuring 7-alkoxycoumarin O-dealkylase activities (O-demethylase, O-deethylase, and O-depropylase) in liver homogenates.

Pharmacological interactions were evaluated using two "probe" drugs:

  1. Diazepam: Muscle relaxation was measured via an inclined screen test, alongside anti-convulsant assays.
  2. Pentobarbital: Anesthesia duration was measured by "sleeping time."

The effects of 480156-S (10–50 mg/kg) were compared with ibuprofen and the known P-450 inhibitor cimetidine.

Key Results

Selective and Cumulative Enzyme Inhibition

A single dose of 480156-S did not significantly affect P-450 activity. However, repeated administration (3–7 days) led to a dose-dependent suppression of specific activities. Notably, the inhibition was highly selective: O-demethylase activity was significantly reduced, while O-depropylase activity remained largely unaffected. This suggests that 480156-S targets specific P-450 isozymes rather than acting as a broad-spectrum inhibitor.

Prolongation of Diazepam Effects

The selective inhibition of liver enzymes translated into significant pharmacological changes. Pre-treatment with 480156-S markedly prolonged the muscle-relaxant and anti-convulsant effects of diazepam.

Effect of pre-treatment with 480156-S (A), ibuprofen (B), and cimetidine (C) on diazepam-induced muscle relaxation in rats.

As shown in Figure 2, the recovery of muscle tone (measured by the degree of inclination) was significantly delayed in rats treated with 480156-S (Panel A) compared to controls. While ibuprofen (Panel B) showed a similar trend, its effect was less pronounced. Cimetidine (Panel C) also caused significant prolongation, but its inhibitory effect was transient, recovering within 24 hours. In contrast, 480156-S-induced inhibition persisted for up to 48 hours post-dose.

Isozyme Specificity: Diazepam vs. Pentobarbital

A critical finding was the lack of interaction between 480156-S and pentobarbital. While cimetidine nearly tripled pentobarbital sleeping time, 480156-S had no effect. This confirms that 480156-S selectively inhibits the isozymes responsible for diazepam metabolism (and its active metabolites like nordiazepam) but does not interfere with the pathways processing pentobarbital.

Conclusion

The NSAID 480156-S acts as a selective, cumulative inhibitor of specific hepatic Cytochrome P-450 isozymes in rats. This inhibition leads to a clinically relevant prolongation of diazepam's pharmacological action. The delay in onset of inhibition (requiring repeated dosing) and its persistence suggest that either the drug itself or a metabolite accumulates to reach inhibitory concentrations. These findings highlight the importance of considering isozyme-specific DDIs during the development and clinical use of new NSAIDs.

Reference: Matsubara, T., et al. (1988). Effect of the nonsteroidal anti-inflammatory drug 480156-S on hepatic drug-metabolizing activity and pharmacological action of diazepam and pentobarbital in rats. Folia pharmacol. japon. 92, 201-213.

Summary updated

Abstract

Effect of the nonsteroidal anti-inflammatory drug 480156-S on liver drug-metabolizing activity was studied in rats, and its effect was compared with that of cimetidine. Cytochrome P-450-dependent 7-alkoxycoumarin O-dealkylase activity was not affected by a single administration of 480156-S, but the activity, especially the O-demethylase but not the O-depropylase, was suppressed dose-dependently by multiple administrations. Pretreatment of rats with phenobarbital caused a diminution of the inhibitory action of 480156-S. Treatment of rats with cimetidine resulted in a marked decrease in the activity, although it recovered 24 hr later. After the pretreatment of animals with 480156-S or reference drugs, the pharmacological action of diazepam was determined using muscle relaxation and inhibitions of electroshock-induced convulsion and pentetrazole-induced clonic convulsion as the indicators. Prolonged pharmacological activity of diazepam was observed when liver drug-metabolizing activity was lowered by the pretreatment. On the other hand, pentobarbital-induced anesthesia was prolonged by the pretreatment of rats with cimetidine, but the anesthesia was not modified by the administration of 480156-S. These results suggest the inhibitory action of 480156-S on a specific form(s) of P-450 isozyme.
BibTeX
@inproceedings{matsubara1988effect,
  author = {Takashi Matsubara and Katsumi Hirose and Hisao Hatakeyama and Hirokuni Jyoyama and Akira Touchi and Shigemi OTSUBO},
  title = {{Effect of the nonsteroidal anti-inflammatory drug 480156-S on hepatic drug-metabolizing activity and pharmacological action of diazepam and pentobarbital in rats.}},
  booktitle = {Folia},
  year = {1988},
  doi = {10.1254/fpj.92.201},
}
Figure